Search results
Results from the WOW.Com Content Network
In community samples, cutoff scores for likely dementia have ranged from 3.3 and above to 3.6 and above, while in patient samples the cutoff scores have ranged from 3.4 and above to 4.0 and above. [3] To improve the detection of dementia, the IQCODE can be used in combination with the Mini-Mental State Examination.
The Self-administered Gerocognitive Examination is a brief cognitive assessment instrument for mild cognitive impairment (MCI) and early dementia, created by Douglas Scharre, Professor of Clinical Neurology and Psychiatry at Ohio State University Wexner Medical Center in Columbus, Ohio. A digital version exists. [1]
Pre-dementia or early-stage dementia (stages 1, 2, and 3). In this initial phase, a person can still live independently and may not exhibit obvious memory loss or have any difficulty completing ...
The Saint Louis University Mental Status (SLUMS) Exam is a brief screening assessment used to detect cognitive impairment. [1] It was developed in 2006 at the Saint Louis University School of Medicine Division of Geriatric Medicine, in affiliation with a Veterans' Affairs medical center. [2]
The following questions are put to the patient. Each question correctly answered scores one point. A score of 7–8 or less suggests cognitive impairment at the time of testing, [4] although further and more formal tests are necessary to confirm a diagnosis of dementia, delirium or other causes of cognitive impairment. Culturally-specific ...
The standard MMSE form which is currently published by Psychological Assessment Resources is based on its original 1975 conceptualization, with minor subsequent modifications by the authors. Advantages to the MMSE include requiring no specialized equipment or training for administration, and has both validity and reliability for the diagnosis ...
The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) is a brief neuropsychological assessment used to assess the severity of cognitive symptoms of dementia. It is one of the most widely used cognitive scales in clinical trials [ 1 ] and is considered to be the “gold standard” for assessing antidementia treatments.
It is scored out of 100, with a higher score denoting better cognitive function. At the recommended cut-off scores of 88 and 83, the ACE was reported to have good sensitivity and specificity for identifying different forms of dementia and other impairments of memory and judgement (0.93 and 0.71; 0.82 and 0.96, respectively). [5]